| 1 |
castration-resistant prostate cancer
(2853 times)
|
Neoplasms
(1269 times)
|
AR (801 times)
PSA (420 times)
PCa (350 times)
|
2006 Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.
|
| 2 |
castration-resistant PCa
(230 times)
|
Neoplasms
(102 times)
|
PCa (148 times)
AR (85 times)
PC (66 times)
|
2008 Mechanisms mediating androgen receptor reactivation after castration.
|
| 3 |
colorectal peritoneal carcinomatosis
(23 times)
|
General Surgery
(10 times)
|
CRS (8 times)
PCI (7 times)
PIC (5 times)
|
2008 Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
|
| 4 |
castration-recurrent PCa
(4 times)
|
Science
(1 time)
|
AR (4 times)
PCa (3 times)
ADT (1 time)
|
2010 Androgen receptor abnormalities in castration-recurrent prostate cancer.
|
| 5 |
cancer peritoneal carcinomatosis
(3 times)
|
General Surgery
(3 times)
|
CRS (3 times)
HIPEC (1 time)
IPC (1 time)
|
2009 Significance of lymph node metastasis in patients with colorectal cancer peritoneal carcinomatosis.
|
| 6 |
castration-recurrent/resistant CaP
(3 times)
|
Neoplasms
(2 times)
|
DHT (3 times)
ADT (2 times)
AR (2 times)
|
2011 Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
|
| 7 |
cancer patients will progress to a castration-resistant state
(2 times)
|
Neoplasms
(1 time)
|
ADT (1 time)
AIS (1 time)
AR (1 time)
|
2016 Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
|
| 8 |
Cancer Rehabilitation Physician Consortium
(2 times)
|
Physical and Rehabilitation Medicine
(2 times)
|
ACSM (1 time)
CRM (1 time)
|
2019 Training and Practice Patterns in Cancer Rehabilitation: A Survey of Physiatrists Specializing in Oncology Care.
|
| 9 |
castrate-resistant prostate cancer patients
(2 times)
|
Medicine
(1 time)
|
CTCs (1 time)
DJD (1 time)
GEDI (1 time)
|
2012 Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.
|
| 10 |
cancer transition from androgen-dependent to androgen-independent state
(1 time)
|
Biochemistry
(1 time)
|
ADT (1 time)
AR (1 time)
EMT (1 time)
|
2015 Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer invivo.
|
| 11 |
castration-recurrent/resistant prostate cancer
(1 time)
|
Urology
(1 time)
|
AND (1 time)
|
2018 Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.
|
| 12 |
castration-resistant PCa cell line VCaP
(1 time)
|
Nuclear Medicine
(1 time)
|
AA (1 time)
ADT (1 time)
PCa (1 time)
|
2015 Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
|
| 13 |
centered rectangular photonic-crystal
(1 time)
|
Nanotechnology
(1 time)
|
DFB (1 time)
HR (1 time)
QCLs (1 time)
|
2015 10-W pulsed operation of substrate emitting photonic-crystal quantum cascade laser with very small divergence.
|
| 14 |
central renal pyelocalyceal complex
(1 time)
|
Urology
(1 time)
|
---
|
1979 Nonobstructive fragmentation of central renal pyelocalyceal echo complex.
|
| 15 |
chemotherapy alone, the treatment of peritoneal carcinomatosis from colorectal cancer
(1 time)
|
General Surgery
(1 time)
|
CRS (1 time)
IPC (1 time)
|
2013 Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?
|
| 16 |
chronic radiation proctocolitis
(1 time)
|
Gastroenterology
(1 time)
|
APC (1 time)
|
2010 The incidence of bacteraemia after argon plasma coagulation in patients with chronic radiation proctocolitis.
|
| 17 |
cisplatin/etoposide-resistant prostate cancer
(1 time)
|
Antineoplastic Agents
(1 time)
|
G-CSF (1 time)
MTD (1 time)
TNBC (1 time)
|
2018 A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
|
| 18 |
concentrates prepared from Channa striatus
(1 time)
|
Chemistry
(1 time)
|
---
|
2012 Physico-chemical, amino acid composition, functional and antioxidant properties of roe protein concentrates obtained from Channa striatus and Lates calcarifer.
|
| 19 |
confound treatment of this 'castration resistant' stage of PCa
(1 time)
|
Neoplasms
(1 time)
|
AR (1 time)
DBD (1 time)
LBD (1 time)
|
2018 Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
|
| 20 |
consecutive rising PSAs
(1 time)
|
Urology
(1 time)
|
ADT (1 time)
EHR (1 time)
PSADT (1 time)
|
2015 Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
|
| 21 |
coordinating rehabilitation and palliative care
(1 time)
|
Medicine
(1 time)
|
---
|
2018 [Coordinating rehabilitation and palliative care].
|
| 22 |
corticosteroid-refractory refractory prostate cancer
(1 time)
|
Nephrology
(1 time)
|
ALP (1 time)
DEX (1 time)
LDH (1 time)
|
2011 Docetaxel as a vital option for corticosteroid-refractory prostate cancer.
|
| 23 |
CR prostate cancer
(1 time)
|
Biological Science Disciplines
(1 time)
|
CR (1 time)
|
2018 Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer.
|
| 24 |
CRPC N-glycan score
(1 time)
|
Natural Science Disciplines
(1 time)
|
AGP (1 time)
BPH (1 time)
PC (1 time)
|
2019 Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.
|
| 25 |
cumulated rate of permanent colostomy
(1 time)
|
Neoplasms
(1 time)
|
CR (1 time)
EBRT (1 time)
|
2012 Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial.
|
| 26 |
hormone-refractory 'castrate-resistant' PC
(1 time)
|
Molecular Biology
(1 time)
|
AR (1 time)
PCs (1 time)
PHB (1 time)
|
2011 Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.
|
A Search Service for Abbreviation / Long Form